SOP for Review and Approval of Method Development Data in AMD
Department | Analytical Method Development |
---|---|
SOP No. | SOP/AMD/027/2025 |
Supersedes | SOP/AMD/027/2022 |
Page No. | Page 1 of 14 |
Issue Date | 19/05/2025 |
Effective Date | 20/05/2025 |
Review Date | 19/05/2026 |
1. Purpose
The purpose of this SOP is to establish a standardized procedure for the systematic review and approval of analytical method development data in the Analytical Method
Development (AMD) department. This ensures that data generated during method development is accurate, complete, traceable, and meets regulatory expectations.
2. Scope
This SOP applies to all personnel involved in generating, reviewing, and approving analytical method development data for APIs, intermediates, and finished products within the AMD department.
3. Responsibilities
- Analytical Scientist: Ensures all development data is documented in a timely, legible, and accurate manner with traceable entries.
- Reviewer (Team Lead or Designee): Conducts detailed verification of raw data, calculations, chromatograms, and summary reports.
- QA Personnel: Audits the data for compliance with GMP and data integrity principles (ALCOA+).
- Head – AMD: Provides final approval of method development summary and ensures readiness for validation.
4. Accountability
The Head of Analytical Method Development is accountable for ensuring the completeness and accuracy of development data and for approving the use of developed methods for validation or regulatory submission.
5. Procedure
5.1 Data Entry and Documentation
- Use bound notebooks or validated electronic systems for recording all method development experiments.
- Include:
- Trial objective
- System and method conditions
- Instrument settings
- Sample preparation details
- Chromatographic/spectroscopic outputs
- Document entries with initials, date, and unique page reference. Record electronically generated results using Annexure-1: Method Development Data Entry Template.
5.2 Primary Review (Scientific Review)
- Performed by Team Lead or Senior Scientist not involved in data generation.
- Check for:
- Method conditions used
- Peak integrity and resolution
- Consistency across injections
- Calculation accuracy
- Ensure traceability of reagents, working standards, instrument calibration records.
- Summarize review comments in Annexure-2: Data Review Checklist.
5.3 Data Integrity and GMP Review
- QA verifies:
- No overwriting or missing pages
- Proper sign/date entries
- Raw data matches processed reports
- Audit trails (if electronic)
- Confirm data complies with ALCOA+ principles:
- Attributable
- Legible
- Contemporaneous
- Original
- Accurate
- Record QA remarks in Annexure-3: Data Integrity Verification Log.
5.4 Approval and Archival
- Following reviews, compile:
- Method Development Protocol
- Final Summary Report
- Validated Graphs and Chromatograms
- Submit for approval by Head – AMD using Annexure-4: Development Data Approval Record.
- Approved methods can proceed for validation protocol preparation.
- Archive originals in central AMD records room with access log.
5.5 Handling Observations and Corrections
- If discrepancies are found:
- Mark correction with a single line strike-through
- Record reason, initials, and date near correction
- Corrective entries must not obscure original data
- Document significant discrepancies and resolution using deviation form SOP/QMS/045/2025.
6. Abbreviations
- AMD: Analytical Method Development
- QA: Quality Assurance
- GMP: Good Manufacturing Practices
- ALCOA+: Attributable, Legible, Contemporaneous, Original, Accurate + Complete, Consistent, Enduring, Available
7. Documents
- Method Development Data Entry Template – Annexure-1
- Data Review Checklist – Annexure-2
- Data Integrity Verification Log – Annexure-3
- Development Data Approval Record – Annexure-4
See also Analytical Method Development: Validation-Readiness Evaluation of Developed Methods - V 2.0
8. References
- ICH Q14 – Analytical Procedure Development
- ICH Q10 – Pharmaceutical Quality System
- WHO TRS 996 – Good Practices for Pharmaceutical Quality Control Laboratories
- MHRA Data Integrity Guidance
9. SOP Version
Version: 2.0
10. Approval Section
Prepared By | Checked By | Approved By | |
---|---|---|---|
Signature | |||
Date | |||
Name | |||
Designation | |||
Department |
11. Annexures
Annexure-1: Method Development Data Entry Template
Date | Analyst | Method Code | Objective | Conditions Used |
---|---|---|---|---|
10/05/2025 | Rajesh Kumar | AMD/045 | Determine degradation separation | HPLC, C18, 0.1% TFA |
Annexure-2: Data Review Checklist
Item | Reviewed? | Comments |
---|---|---|
Chromatogram Peak Integrity | Yes | All resolved |
System Suitability Compliance | Yes | RSD within 1.5% |
Annexure-3: Data Integrity Verification Log
Document | Integrity Check | Findings | QA Reviewer |
---|---|---|---|
Notebook Entry 12–18 | Pass | No anomalies | Sunita Reddy |
Annexure-4: Development Data Approval Record
Method ID | Approved By | Date | Remarks |
---|---|---|---|
AMD/045 | Dr. Vinay Pawar | 15/05/2025 | Ready for validation |
Revision History:
Revision Date | Revision No. | Details | Reason | Approved By |
---|---|---|---|---|
04/05/2025 | 2.0 | Added Annexure-4 and electronic data audit trail checks | Regulatory inspection finding |